Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

Brachat A. H. , Grom A. A. , Wulffraat N., Brunner H. I. , Quartier P., Brik R., ...More

ARTHRITIS RESEARCH & THERAPY, vol.19, 2017 (Journal Indexed in SCI) identifier identifier identifier


Background: Canakinumab is a human anti-interleukin-1 beta (IL-1 beta) monoclonal antibody neutralizing IL-1 beta-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA).